Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05030129 · ClinicalTrials.gov registry record · Phase 2

ERG/5-HTP in Fragile X Syndrome (FXS)

A Phase 2 study of Fragile X Syndrome, sponsored by Elizabeth Berry-Kravis.

Completed
Registry status
Phase 2
Development phase
15
Enrollment target
1
Study location

NCT05030129 is a Phase 2 study of Fragile X Syndrome that has completed, run by Elizabeth Berry-Kravis. The registered enrollment target is 15 participants, below the 101-participant average among 16 other Fragile X Syndrome trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05030129, a Phase 2 study of Fragile X Syndrome, has completed, sponsored by Elizabeth Berry-Kravis.

COMPLETED
Registry status
Phase 2
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the safety, tolerability and efficacy of Ergoloid mesylates (EM) and 5-hydroxytryptophan (5-HTP) and the combination (EM + 5-HTP) compared to placebo in males aged 18-45 years old with Fragile X Syndrome.

Conditions Studied

Fragile X Syndrome

Interventions

  • DRUG 5-Hydroxytryptophan
  • DRUG Ergoloid Mesylates
  • DRUG Matching placebo for Ergoloid mesylates
  • DRUG Matching placebo for 5-Hydroxytryptophan

Study Locations (1)

Illinois

  • Rush University Medical Center - Chicago

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2021-10-07
Est. Completion 2023-01-19
Phase Phase 2

Sponsor

Elizabeth Berry-Kravis

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05030129

The ClinicalTrials.gov registry entry for NCT05030129 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101-participant average among 16 other Fragile X Syndrome trials with a reported enrollment target (85% lower). The listed sponsor is Elizabeth Berry-Kravis, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Fragile X Syndrome appearing as the primary indexed condition, and to 4 interventions - of which 5-Hydroxytryptophan is the first listed.

NCT05030129 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT05030129 about?

NCT05030129 is a clinical study titled "ERG/5-HTP in Fragile X Syndrome (FXS)". The purpose of this study is to assess the safety, tolerability and efficacy of Ergoloid mesylates (EM) and 5-hydroxytryptophan (5-HTP) and the combination (EM + 5-HTP) compared to placebo in males aged 18-45 years old with Fragile X Syndrome.

What is the current status of trial NCT05030129?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2021-10-07. Estimated completion is 2023-01-19.

What conditions does trial NCT05030129 study?

This clinical trial studies the following conditions: Fragile X Syndrome.

What interventions are being tested in trial NCT05030129?

The interventions under investigation include: 5-Hydroxytryptophan (DRUG), Ergoloid Mesylates (DRUG), Matching placebo for Ergoloid mesylates (DRUG), Matching placebo for 5-Hydroxytryptophan (DRUG).

Who is sponsoring clinical trial NCT05030129?

This trial is sponsored by Elizabeth Berry-Kravis, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05030129 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Fragile X Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Fragile X Syndrome

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.